Latest news with #MedicarePartD
Yahoo
2 hours ago
- Business
- Yahoo
Retirees face staggering 6-figure health care bill when leaving the workforce
A 65-year-old retiring in 2025 can expect to pay $172,500 on average for healthcare and medical expenses throughout retirement. That's according to Fidelity's 2025 Retiree Health Care Cost Estimate, which is up 4% from the year before. It highlights the general upward trajectory of health-related expenses that have occurred since Fidelity's first estimate of $80,000 in 2002. The report underscores an even bigger issue: 17% of all respondents have taken no action at all when it comes to planning for health expenses in retirement. One in five respondents said they never consider healthcare needs during retirement. With Gen X, that rises to about one in four. Health Care Costs For Retirees Continue To Soar Fidelity's estimate assumes enrollment in Medicare (Parts A and B) and Medicare Part D, which includes premiums, co-payments and other out-of-pocket costs for medical care and prescription drugs. However, it does not include long-term care expenses. For instance, even with Medicare, retirees are responsible for Medicare premiums, over-the-counter medications, dental and vision care as well as other types of added expenses like long-term care, according to Fidelity. Some of those costs can be offset with enrollment in Medicare Advantage plans, but those require separate monthly premiums. Read On The Fox Business App Chandler Riggs, vice president of financial consultancy at Fidelity Investments, told FOX Business that the rise in healthcare costs is driven by several factors, notably longer life expectancies, as well as a healthcare inflation rate that has outpaced general inflation. Despite the daunting figure, Riggs called Fidelity's estimate an "important wake-up call for all generations." "It's not just a benchmark for retirement readiness but also underscores the importance of planning as early as possible," Riggs said. Social Security Confidence Hits 15-Year Low As Younger Americans Increasingly Lose Faith In System Matthew Gregory, planning director for private wealth management firm The Bahnsen Group, said people grow accustomed to a hands-off approach during their working years since a meaningful piece of the cost can come directly out of their paycheck. "They may not be thinking about the need for supplemental coverage on top of Parts A and B of Medicare, as well as the fact that Medicare does not cover most long-term care costs. Those expenses can snowball quickly and become a reality check," he said. Likewise, Riggs said that people who have health coverage through their employer won't consider how they'll cover medical expenses when they retire and are no longer enrolled in their employer's health plan. This wake-up call for people near retirement could force them to question whether they have saved enough for retirement, if they can accomplish their goals with the funds they have and if they need to delay retirement entirely. "They may also end up settling for a level of coverage that is far less than they would otherwise be comfortable with or leaning on family members to fill gaps in care," Gregory said. This data comes shortly after an AARP study found Americans' confidence in Social Security – often seen as a safety net program because it provides a financial foundation for retirees – was also on the decline. The data, which was published earlier this week, showed that Americans' overall confidence in Social Security dropped from 43% in 2020 to 36% in 2025, the lowest level since it fell to 35% in 2010. Despite these findings on retirement readiness and growing uncertainty about long-term financial support, Riggs underscored that there are always steps someone can take to better position themselves financially, regardless of where they are in their retirement journey. Riggs said saving early and leveraging accounts where savings can be invested are powerful tools to build a "healthcare nest egg, regardless of age." Additionally, Riggs said employees who are enrolled in an HSA-eligible health plan should consider using a health savings account. For one, the triple-tax advantage of HSAs makes them a versatile tool to save and pay for health expenses. The contributions are tax-deductible, and the HSA dollars can be spent tax-free when used for qualified medical expenses. Any potential growth in money invested is tax-free as well, Riggs article source: Retirees face staggering 6-figure health care bill when leaving the workforce
Yahoo
2 days ago
- Business
- Yahoo
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ...
Net Revenue: $156.8 million in Q2 2025, a 52% year-over-year increase. ARCALYST Net Sales Guidance: Raised to $625 million to $640 million for full year 2025. Net Income: $17.8 million in Q2 2025, compared to a net loss of $3.9 million in Q2 2024. Operating Expenses: Grew 26% year-over-year in Q2 2025. ARCALYST Collaboration Profit: $104.8 million in Q2 2025, a 75% year-over-year increase. Cash Balance: Increased by approximately $40 million to $307.8 million in Q2 2025. Warning! GuruFocus has detected 3 Warning Sign with GPK. Release Date: July 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Kiniksa Pharmaceuticals International PLC (NASDAQ:KNSA) reported strong revenue growth for ARCALYST, with net revenue reaching $156.8 million in Q2 2025, a 52% year-over-year increase. The company surpassed $1 billion in cumulative net sales for ARCALYST, demonstrating effective commercial strategy and execution. Kiniksa raised its full-year 2025 ARCALYST net sales guidance to between $625 million and $640 million, up from the previous range of $590 million to $605 million. The company has initiated and begun recruiting for the Phase 2/Phase 3 clinical trial of KPL-387, aiming to deliver this treatment option by 2028-2029. Kiniksa's strong financial performance has resulted in a net income of $17.8 million in Q2 2025, compared to a net loss of $3.9 million a year ago, and an increased cash balance of $307.8 million. Negative Points Operating expenses grew 26% year-over-year in Q2 2025, driven by cost of goods sold and collaboration expenses related to ARCALYST revenue growth. The onetime bolus of Medicare Part D patients observed in Q1 will not repeat, potentially impacting future growth rates. Despite strong performance, the company faces emerging competition, including potential oral competitors, which could impact market share. The company has not yet announced specific indications for KPL-1161, leaving uncertainty about its future market potential. Kiniksa's continued growth and expansion efforts may require further investment, potentially impacting cash flow and financial stability. Q & A Highlights Q: Congrats on the quarter. Can you provide commentary on the trends you're seeing in the first recurrent setting, given that 20% of total prescriptions are coming from this setting? A: Yes, we've seen continuous increase in penetration into the 2-plus recurrence group, now at 15%. We've also observed significant growth in early stages of the disease, with around 20% of ARCALYST patients prescribed during their first recurrence. This reflects greater confidence and familiarity among healthcare professionals with prescribing ARCALYST early in the disease course. Q: When you look at patients who've dropped off, was dosing frequency a big driver? How do you see the new start outlook for KPL-387? A: Patients are staying on ARCALYST for an average of 30 months with high compliance. The opportunity for ARCALYST remains significant, especially with 15% penetration. Regarding KPL-387, we are excited about its potential and are leveraging our experience with ARCALYST to ensure successful commercialization. Q: Given the pace of growth, how do you think about expanding the sales force or marketing efforts to drive penetration? A: We continuously analyze the right size for our sales force, currently around 85, and explore new marketing strategies, including digital marketing and AI, to enhance our reach. We are committed to evolving our approach to maximize ARCALYST's potential. Q: On ARCALYST, are you seeing a shorter treatment duration in first recurrence patients compared to those with multiple recurrences? A: We haven't observed significant differences in treatment duration between first recurrence and multiple recurrence patients. The average duration is 30 months, with a median of 17 months, and a restart rate of around 45%. Q: Regarding KPL-387, what is the target efficacy profile, and how do you plan to balance cash flow with initiating studies in new indications? A: For KPL-387, we aim to select a dose that effectively treats acute flares and prevents subsequent ones, similar to ARCALYST. We are focused on maintaining cash flow positivity while advancing our pipeline and exploring strategic initiatives. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ...
Net Revenue: $156.8 million in Q2 2025, a 52% year-over-year increase. ARCALYST Net Sales Guidance: Raised to $625 million to $640 million for full year 2025. Net Income: $17.8 million in Q2 2025, compared to a net loss of $3.9 million in Q2 2024. Operating Expenses: Grew 26% year-over-year in Q2 2025. ARCALYST Collaboration Profit: $104.8 million in Q2 2025, a 75% year-over-year increase. Cash Balance: Increased by approximately $40 million to $307.8 million in Q2 2025. Warning! GuruFocus has detected 3 Warning Sign with GPK. Release Date: July 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Kiniksa Pharmaceuticals International PLC (NASDAQ:KNSA) reported strong revenue growth for ARCALYST, with net revenue reaching $156.8 million in Q2 2025, a 52% year-over-year increase. The company surpassed $1 billion in cumulative net sales for ARCALYST, demonstrating effective commercial strategy and execution. Kiniksa raised its full-year 2025 ARCALYST net sales guidance to between $625 million and $640 million, up from the previous range of $590 million to $605 million. The company has initiated and begun recruiting for the Phase 2/Phase 3 clinical trial of KPL-387, aiming to deliver this treatment option by 2028-2029. Kiniksa's strong financial performance has resulted in a net income of $17.8 million in Q2 2025, compared to a net loss of $3.9 million a year ago, and an increased cash balance of $307.8 million. Negative Points Operating expenses grew 26% year-over-year in Q2 2025, driven by cost of goods sold and collaboration expenses related to ARCALYST revenue growth. The onetime bolus of Medicare Part D patients observed in Q1 will not repeat, potentially impacting future growth rates. Despite strong performance, the company faces emerging competition, including potential oral competitors, which could impact market share. The company has not yet announced specific indications for KPL-1161, leaving uncertainty about its future market potential. Kiniksa's continued growth and expansion efforts may require further investment, potentially impacting cash flow and financial stability. Q & A Highlights Q: Congrats on the quarter. Can you provide commentary on the trends you're seeing in the first recurrent setting, given that 20% of total prescriptions are coming from this setting? A: Yes, we've seen continuous increase in penetration into the 2-plus recurrence group, now at 15%. We've also observed significant growth in early stages of the disease, with around 20% of ARCALYST patients prescribed during their first recurrence. This reflects greater confidence and familiarity among healthcare professionals with prescribing ARCALYST early in the disease course. Q: When you look at patients who've dropped off, was dosing frequency a big driver? How do you see the new start outlook for KPL-387? A: Patients are staying on ARCALYST for an average of 30 months with high compliance. The opportunity for ARCALYST remains significant, especially with 15% penetration. Regarding KPL-387, we are excited about its potential and are leveraging our experience with ARCALYST to ensure successful commercialization. Q: Given the pace of growth, how do you think about expanding the sales force or marketing efforts to drive penetration? A: We continuously analyze the right size for our sales force, currently around 85, and explore new marketing strategies, including digital marketing and AI, to enhance our reach. We are committed to evolving our approach to maximize ARCALYST's potential. Q: On ARCALYST, are you seeing a shorter treatment duration in first recurrence patients compared to those with multiple recurrences? A: We haven't observed significant differences in treatment duration between first recurrence and multiple recurrence patients. The average duration is 30 months, with a median of 17 months, and a restart rate of around 45%. Q: Regarding KPL-387, what is the target efficacy profile, and how do you plan to balance cash flow with initiating studies in new indications? A: For KPL-387, we aim to select a dose that effectively treats acute flares and prevents subsequent ones, similar to ARCALYST. We are focused on maintaining cash flow positivity while advancing our pipeline and exploring strategic initiatives. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
2 days ago
- Business
- Globe and Mail
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AstraZeneca 's AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of $2.17 per share rose 10% year over year on a reported basis and 12% on a constant exchange rate (CER). Total revenues of $14.46 billion rose 12% on a reported basis and 11% at CER, driven by higher product sales and alliance revenues from partnered medicines. Revenues beat the Zacks Consensus Estimate of $14.03 billion. All growth rates mentioned below are on a year-over-year basis and at CER. AZN's Product Sales & Alliance Revenues Among AstraZeneca's various therapeutic areas, Oncology revenues were up 18%, while Cardiovascular, Renal and Metabolism ('CVRM') product sales rose 3%. The Respiratory & Immunology (R&I) segment's sales rose 12%. While Rare disease revenues rose 7%, sales of Vaccines & Immune (V&I) Therapies rose 54%. Sales of other medicines were down 9%. Product sales rose 10% to $13.8 billion, as strong underlying demand trends for its products were partially offset by new manufacturer discounts under Medicare Part D redesign in the United States. Alliance revenues include royalties and profit share from partnered medicines, such as Enhertu and Tezspire, in geographies where its partner books product sales. Alliance revenues rose 35% to $654 million, driven by continued revenue growth from partnered medicines. Alliance revenues included $436 million from Daiichi Sankyo for Enhertu and $155 million of AstraZeneca's share of gross profits in the United States from partner Amgen AMGN for Tezspire. Alliance revenues also included $10 million from partner Daiichi Sankyo for Datroway and $27 million for Beyfortus. AZN records a 50% share of gross profits from Beyfortus' sales in major ex-U.S. markets and 25% of brand revenues from the rest of the world markets received from partner Sanofi SNY. The company also records Beyfortus product sales from products supplied to partner Sanofi under the V&I Therapies segment. AstraZeneca's Key Oncology Drugs Beat Estimates Here, we have discussed the total revenues of its drugs by including Alliance revenues and Collaboration revenues within each revenue figure. In Oncology, Tagrisso recorded revenues of $1.81 billion, up 12% year over year, on strong demand for all indications and in all regions, which more than offset the impact of Medicare Part D redesign and pricing pressure in some European markets. Tagrisso sales beat the Zacks Consensus Estimate as well as our model estimate of $1.75 billion. Lynparza's total revenues rose 11% to $838 million, driven by increased market share/demand growth for all approved indications. The drug's sales beat the Zacks Consensus Estimate of $810 million and our estimate of $788.7 million. AstraZeneca markets Lynparza in partnership with Merck MRK. During the quarter, the company did not record any milestone payment from partner Merck related to the drug. Imfinzi generated sales of $1.46 billion in the quarter, up 26%, driven by strong growth from launch in bladder and lung cancer indications, partially offset by mandatory price reductions in Japan. Imfinzi sales beat the Zacks Consensus Estimate of $1.37 billion and our estimate of $1.3 billion. Sales of Calquence rose 10% to $872 million in the quarter. New breast cancer drug Truqap recorded $170 million in revenues in the second quarter of 2025 compared with $132 million in the previous quarter. Newly approved drug Datroway, for which it has a partnership with Daiichi Sankyo, recorded revenues of $11 million in the quarter compared with $4 million in the first quarter, driven by encouraging initial launch uptake in the United States. The FDA approved the expanded use of Datroway for a second indication — non-small cell lung cancer in June. AZN's CVRM Segment Performance In CVRM, Farxiga recorded product sales of $2.15 billion, up 10%, driven by continued demand growth across chronic kidney disease and heart failure. Farxiga sales beat the Zacks Consensus Estimate of $2.05 billion and our model estimate of $2.06 billion. Brilinta/Brilique sales totaled $215 million in the reported quarter, down 38%, due to the generic launch in Europe and the United States in the second quarter. New drug Wainua recorded $44 million in product sales during the quarter compared with $39 million in the previous quarter, driven by strong launch momentum in the United States and initial launch in ex-U.S. markets. AZN's R&I Segment Performance In R&I, Symbicort sales declined 1% to $715 million due to generic erosion in Europe and competition from triple therapy on the ICS/LABA class of medicines like Symbicort in China. The drug's sales missed the Zacks Consensus Estimate and our model estimate of $726 million and $732.9 million, respectively. Fasenra recorded sales of $502 million in the quarter, up 18% year over year, driven by strong demand growth and market share gains. The recent launch for the EGPA indication also benefited sales in some countries. The drug's sales beat the Zacks Consensus Estimate as well as our model estimate of$467 million. Breztri recorded sales of $283 million, up 20% year over year. Pulmicort sales declined 32% to $106 million. Tezspire recorded total revenues of $261.0 million, up 65% year over year, driven by demand growth and launch uptake in multiple markets. Amgen records product sales in the United States, and AstraZeneca records its share of U.S. gross profits as Alliance revenues. AstraZeneca books product sales in markets outside the United States. New product Airsupra generated $42 million in product sales in the second quarter, compared with $28 million in the previous quarter. New lupus drug, Saphnelo, recorded sales of $167 million, up 48% year over year. AZN's Rare Disease, V&I and Other Segment In the Rare Disease portfolio, Soliris sales fell 22% to $530 million due to conversion to Ultomiris and biosimilar erosion in Europe. Ultomiris revenues amounted to $1.18 billion, up 23%, driven by patient demand, growth in neurology indications, geographic expansions in new markets and continued conversion from Soliris. The impact of Medicare Part D redesign was minimal in the second quarter. In Other Medicines, sales of Nexium declined 11% to $201 million. In V&I Therapies, AstraZeneca recorded $126 million in revenues from Beyfortus, which included alliance revenues mentioned earlier as well as sales of manufactured Beyfortus product to Sanofi. AZN Maintains 2025 Guidance AstraZeneca maintained its financial guidance for 2025. It expects total revenues to grow by a high single-digit percentage at CER. Core EPS is expected to increase by a low double-digit percentage. Our Take on AZN's Results AstraZeneca reported decent second-quarter results, as its earnings matched estimates and revenues beat the same. Sales of almost all key drugs, including Tagrisso, Lynparza, Imfinzi, Farxiga and Fasenra beat estimates. All these drugs have been driving AstraZeneca's top-line growth over the past several quarters, backed by increasing demand trends. Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap also contributed to top-line growth in the second quarter. AstraZeneca also announced an increase in its interim dividend by 3% to $1.03 per share. Shares of the British drugmaker rose around 4% in pre-market trading on Tuesday in response to the strong top-line performance. Year to date, the stock has risen 11.1% compared with the industry 's 3.1% increase. AZN reaffirmed its 2025 guidance. Despite the potential impact from Part D redesign, AstraZeneca expects total revenues to grow by a high single-digit percentage at CER in 2025. Growth momentum in the Oncology and CVRM segments is expected to continue in 2025. However, in Rare Disease, though AstraZeneca expects growth in 2025, it will be at a slower pace than in 2024. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. AstraZeneca expects to generate$80 billion in total revenues by 2030, a significant increase from the $54 billion it generated in 2024. By the said time frame, AstraZeneca plans to launch 20 new medicines, with almost half of these already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. The company is also on track to achieve a mid-30s percentage core operating margin by 2026 Earlier this month, AZN announced plans to invest $50 billion by 2030 to boost manufacturing and R&D in the United States to expand domestic production in response to ongoing tariff pressures under President Donald Trump. AZN's Zacks Rank Currently, AstraZeneca has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Higher. Faster. Sooner. Buy These Stocks Now A small number of stocks are primed for a breakout, and you have a chance to get in before they take off. At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We've combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month. You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days. Download the report free now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report
Health Line
24-07-2025
- Health
- Health Line
Medicare's Limited Income Newly Eligible Transition (LI NET) Program
LI NET Medicare gives temporary drug coverage to people from low income households who haven't yet enrolled in a Part D. It covers all drugs that Part D covers, allowing you to visit any pharmacy. Medicare launched the Limited Income Newly Eligible Transition (LI NET) Program in 2010 to provide temporary Part D prescription drug coverage for beneficiaries from low-income households who have yet to join a Medicare drug plan. In 2024, LI NET became a permanent part of the Medicare Part D program due to Section 118 of the Consolidated Appropriations Act of 2021. Humana currently administers the LI NET program nationwide. What is LI NET in Medicare? Unlike Original Medicare (parts A and B), which is a government-run insurance plan, private insurers operate Medicare Part D drug plans. There are many different Part D plans, and depending on the plan you select, your exact benefits and costs will vary. However, if you live on a lower income and are eligible for Medicare but haven't yet enrolled in a Part D plan, you can qualify for the LI NET program under certain criteria. LI NET coverage lasts up to 2 months, giving you time to choose and sign up for a Part D plan that fits your needs. Once you qualify, your enrollment in LI NET begins on the first day of the month when you become eligible and continues for 2 months. Some people may be eligible for retroactive coverage. If this applies to you, you can get reimbursed for any qualifying prescriptions from when you became eligible for LI NET or 36 days before you signed up for Part D coverage, whichever comes later. Am I eligible for LI NET Medicare? Depending on how you qualify for LI NET, your exact coverage may vary slightly as follows: You're dually enrolled in full-benefit Medicare and Medicaid: 36 months of retroactive coverage. You're eligible for Supplemental Security Income (SSI): 36 months of retroactive coverage. You're eligible for Extra Help: 30 days of retroactive pharmacy counter coverage. You're eligible for certain Medicare Savings Programs (MSPs): 30 days of retroactive pharmacy counter coverage. Pharmacy counter coverage means that when you pick up your medication, you will automatically pay reduced pricing according to your plan. What medications can I get through LI NET Medicare? Each full Part D plan typically covers specific medications, determined by the plan's formulary. However, LI NET maintains an open formulary, which means this program covers all medications that Part D plans can cover. Exceptions include those that Part D never covers or those that federal law prohibits. However, you might need to provide proof of a particular diagnosis to secure coverage for certain medications under LI NET. This program does not restrict network pharmacies, which means you can visit any pharmacy you want. Frequently asked questions Does LI NET have premiums, deductibles, or copays? You don't have a monthly premium or a deductible with LI NET. However, you may have a copay when you purchase prescription drugs. However, this will depend on how you're eligible and your eligibility level. You don't have a monthly premium or a deductible with LI NET. However, you may have a copay when you purchase prescription drugs. However, this will depend on how you're eligible and your eligibility level. How do I fill a prescription in a pharmacy with LI NET? In order for your pharmacy to bill LI NET, the pharmacist may be able to find this within the Medicare system. Alternatively, you may need to show the pharmacist your Medicaid card or another document that verifies either your Medicaid eligibility or your eligibility for Extra Help. Once they have a reasonable expectation of your eligibility, the pharmacy will generally bill your medications directly to the LI NET program. In order for your pharmacy to bill LI NET, the pharmacist may be able to find this within the Medicare system. Alternatively, you may need to show the pharmacist your Medicaid card or another document that verifies either your Medicaid eligibility or your eligibility for Extra Help. Once they have a reasonable expectation of your eligibility, the pharmacy will generally bill your medications directly to the LI NET program. How do I contact Medicare with questions about LI NET? For information about Medicare's LI NET Program, call the LI NET help desk at 1-800-783-1307 between 8 a.m. and 11 p.m. Eastern Time (ET). TTY users should call 711. For information about Medicare's LI NET Program, call the LI NET help desk at 1-800-783-1307 between 8 a.m. and 11 p.m. Eastern Time (ET). TTY users should call 711. Takeaway Medicare Part D provides prescription drug coverage through private insurance companies, with costs varying depending on the plan you choose. The LI NET Program, started in 2010 and made a permanent option in 2024, can offer you temporary Part D coverage if you're living on a low income and haven't yet joined a full Part D plan. With LI NET, you can get immediate drug coverage for up to two months, allowing you time to select and enroll in your preferred Part D plan. Humana manages the LI NET program, which features an open formulary and allows you to use any pharmacy without restrictions. The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
